Your browser doesn't support javascript.
loading
Novel applications of recombinant erythropoietin.
Sharples, Edward J; Thiemermann, Christoph; Yaqoob, Magdi M.
Afiliação
  • Sharples EJ; Centre for Experimental Medicine, Nephrology and Critical Care, William Harvey Research Institute, Queen Mary, University of London, Charterhouse Square, London EC1M 6BQ, UK.
Curr Opin Pharmacol ; 6(2): 184-9, 2006 Apr.
Article em En | MEDLINE | ID: mdl-16483842
ABSTRACT
Recombinant erythropoietin (EPO) was introduced into clinical practice after the identification of EPO as the major haemopoietic growth factor determining survival and maturation of erythroid precursors. Advances in our understanding of the novel sites of action of EPO in the vasculature, brain, heart and kidney have opened new avenues of therapeutic potential for EPO, and have led to an increased understanding of the biological roles of EPO and its mechanisms of cell protection.
Assuntos
Buscar no Google
Base de dados: MEDLINE Assunto principal: Eritropoetina / Infarto do Miocárdio Idioma: En Ano de publicação: 2006 Tipo de documento: Article
Buscar no Google
Base de dados: MEDLINE Assunto principal: Eritropoetina / Infarto do Miocárdio Idioma: En Ano de publicação: 2006 Tipo de documento: Article